All In Biotech

Drug Trial Radar · NCT05457257

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

A Randomized, Open-label Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Chinese Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (PROfound-CN)

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

43

Actual

Start

Jul 29, 2022

Primary completion

Oct 22, 2024

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Foundation Medicine; Myriad Genetics, Inc.
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • olaparibDrug

    300 mg (2x 150 mg tablets) twice daily

  • enzalutamideDrug

    160 mg (4 x 40 mg capsules) once daily

  • abiraterone acetateDrug

    1,000 mg (4 x 250 mg tablets) once daily

  • PrednisoneDrug

    5mg(5mg x 1 tablet) twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)Time frame: Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Bengbu, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Jiaxing, China

  • Research Site

    Jinan, China

  • Research Site

    Jinan, China

  • Research Site

    Jining, China

  • Research Site

    Kunming, China

  • Research Site

    Lanzhou, China

  • Research Site

    Linyi, China

  • Research Site

    Nanchang, China

  • Research Site

    Nantong, China

  • Research Site

    Ningbo, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Suzhou, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Wanzhou, China

  • Research Site

    Wuhan, China

  • Research Site

    Wuxi, China

  • Research Site

    Wuxi, China

  • Research Site

    Xi'an, China

  • Research Site

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.